News and Announcements

For media inquiries:
Wade Lange
e: wadelange@immuneworks.com


Results of the ImmuneWorks Phase 1b IPF clinical trial published in the European Respiratory Journal

http://www.immuneworks.com/headlines/results-immuneworks-phase-1b-ipf-clinical-trial-published-european-respiratory-journal

Results of ImmuneWorks Phase 1b IPF clinical trial were published in the European Respiratory Journal [February 18, 2015] ImmuneWorks’ Phase 1b IPF clinical trial results were published in the European Respiratory Journal in January 2015. To view the results of the study please click on the link below or visit our Publications & Presentations page:… Read More


Dr. David Wilkes Honored at Minority Achievers Awards Dinner

http://www.immuneworks.com/headlines/wilkes-minority-achievers-award

Dr. David S. Wilkes was recently honored at the Center for Leadership Development’s Minority Achievers Awards Dinner on March 26th, 2014. To read more please visit:IUPUI Newsroom


ImmuneWorks to present clinical trial results at the 13th Annual Needham Healthcare Conference

http://www.immuneworks.com/headlines/immuneworks-presents-at-needham-healthcare-conference

[APRIL 1, 2014] ImmuneWorks, Inc., a biotechnology company developing novel therapeutics for patients with serious lung diseases, will present at the 13th Annual Needham Healthcare Conference, April 9th at 10:40am in New York, New York. President and CEO Wade A. Lange will present on behalf of ImmuneWorks. ImmuneWorks will showcase the results of its Phase… Read More


Dr. David Wilkes Presents ImmuneWorks Asset at PFF Summit 2013

http://www.immuneworks.com/headlines/immuneworks-presentation-ppf-summi

[December 17, 2013] Dr. David S. Wilkes, Co-founder and Chief Scientific Officer of ImmuneWorks, presented results of the Company’s Phase 1 IPF clinical trial at the 2013 Pulmonary Fibrosis Foundation Summit. To view the presentation, please click on the following link: ImmuneWorks PFF Summit Presentation.


ImmuneWorks Interview on Sound Medicine

http://www.immuneworks.com/headlines/immuneworks-interview-sound-medicine

Wade Lange, President & CEO of ImmuneWorks, was interviewed for a piece on translational medicine on Sound Medicine. Translational medicine has been defined as all the knowledge it takes to a get a molecule from the laboratory bench to the pill bottle on the bedside table. ImmuneWorks is using translational methods to develop treatments for serious… Read More


ImmuneWorks Co-Founder Selected to be the National Program Director of Harold Amos Medical Faculty Development Program

http://www.immuneworks.com/headlines/immuneworks-co-founder-selected-national-program-director-harold-amos-medical-faculty-development-program

ImmuneWorks Co-Founder David S. Wilkes, MD Selected to be the National Program Director of the Robert Wood Johnson Foundation’s Harold Amos Medical Faculty Development Program [JUNE 25, 2013] ImmuneWorks, Inc., congratulates one of the company’s co-founders David S. Wilkes, MD for his selection as the National Program Director of the Robert Wood Johnson Foundation’s Harold… Read More


ImmuneWorks Presents Promising Results from Clinical Trial at ATS

http://www.immuneworks.com/headlines/immuneworks-presents-promising-results-clinical-trial-ats

ImmuneWorks Presents Promising Results from Clinical Trial of IW001 in Patients with Idiopathic Pulmonary Fibrosis at American Thoracic Society Conference [JUNE 19, 2013] ImmuneWorks, Inc., a biotechnology company developing novel therapeutics for patients with serious lung diseases, presented data from their IW001-01 clinical trial in an oral presentation at the 2013 American Thoracic Society (ATS)… Read More


ImmuneWorks to present clinical trial data at the 12th Annual Needham Healthcare Conference

http://www.immuneworks.com/headlines/immuneworks-present-clinical-trial-data-12th-annual-needham-healthcare-conference

ImmuneWorks to present clinical trial data at the 12th Annual Needham Healthcare Conference [APRIL 26, 2013] ImmuneWorks, Inc., a biotechnology company developing novel therapeutics for patients with serious lung diseases, will present at the 12th Annual Needham Healthcare Conference, May 1 at 11:00 a.m., in Chicago, Illinois. President and CEO Wade A. Lange will present… Read More


ImmuneWorks to Present at 2013 ISHLT Annual Meeting and BIO

http://www.immuneworks.com/headlines/immuneworks-present-2013-ishlt-annual-meeting-bio

ImmuneWorks to Present at 2013 International Society for Heart and Lung Transplantation Annual Meeting and BIO International Convention’s Business Forum [APRIL 18, 2013] ImmuneWorks, Inc., a biotechnology company developing novel therapeutics for patients with serious lung diseases, will present a poster showcasing its lung disease-fighting compound at The International Society for Heart and Lung Transplantation… Read More


ImmuneWorks Completes Phase 1 Clinical Trial

ImmuneWorks completed its Phase 1 clinical trial of Type V Collagen oral solution (IW001) in patients suffering from idiopathic pulmonary fibrosis (IPF).


ImmuneWorks Sponsors Pulmonary Fibrosis Foundation’s Inaugural IPF Summit 2011: From Bench to Bedside Scientific Conference

ImmuneWorks is a sponsor of the Pulmonary Fibrosis Foundation’s inaugural “IPF Summit 2011: From Bench to Bedside” scientific conference. Read More


ImmuneWorks Supports Pulmonary Fibrosis Week by Increasing National Recruitment Efforts to Enroll Idiopathic Pulmonary Fibrosis (IPF) Patients in Clinical Trial

Biotechnology firm, ImmuneWorks, is ramping up efforts to support National Pulmonary Fibrosis (PF) Awareness Week (September 18-24). IPF is one of the most fatal, yet publicly unrecognized, diseases claiming more and more lives every year. Read More


Biotechnology Firm ImmuneWorks Begins National Clinical Trial for New Idiopathic Pulmonary Fibrosis (IPF) Investigational Treatments

ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotechnology firm one step closer to commercialization of its lead IPF treatment compound. Read More


ImmuneWorks Lead Product Receives FDA Orphan Drug Designation

ImmuneWorks announces that the U.S. Food and Drug Administration (FDA) recently designated IW001 (bovine Type V Collagen oral solution) as an Orphan Drug. Orphan drugs are those drugs that are intended to be used in populations smaller than 200,000 patients in the United States. Read More


BioCrossroads’ Indiana Seed Fund invests in biotech company developing lung disease treatments

Each year more than 40,000 people die of idiopathic pulmonary fibrosis (IPF), a devastating lung disease – leading to the same number of deaths as breast cancer. Currently, there is no effective treatment for the disease. However, ImmuneWorks, an Indianapolis-based biotechnology company committed to developing effective treatments for serious lung diseases, is developing a safe and effective treatment for IPF patients. Read More


BIOWorld Today Names ImmuneWorks as Leading Innovation in its 2008 Report

ImmuneWorks, Inc is pleased to announce that BioWorld, a leading publication covering the global biotechnology sector included the Indianapolis-based company in its annual listing of leading innovations, Innovations in Biotechnology 2008. “We are gratified that the global biotechnology community recognizes the innovative science underlying ImmuneWorks. Most importantly, we are working aggressively to translate the science that BioWorld recognized into real world treatments for such a deadly disease as Idiopathic Pulmonary Fibrosis,” stated David S. Wilkes, MD ImmuneWorks founder and Chief Science Officer. Read More


Indianapolis Business Journal Health Care and Life Sciences Weekly Features Q&A with Wade Lange

Local biotechnology startup ImmuneWorks LLC is attempting to develop treatment for autoimmune diseases in human lungs. Life science industry veteran Wade Lange became its CEO this summer. Read More


The Indianapolis Star Features ImmuneWorks’ Goal to Help Patients Breathe Easier

When Teresa Geiger attended a lung disease conference five years ago, she could count on one hand the number of meetings dedicated to something called idiopathic pulmonary fibrosis. Read More


TherapeuticsDaily.com: ImmuneWorks Names CEO; Plans Clinical Trials In IPF

Founded less than two years ago to exploit a discovery by researchers at Indiana University on the role of Type V collagen in lung transplant rejection, start-up ImmuneWorks LLC is ready to start pushing its first program into the clinic aimed at idiopathic pulmonary fibrosis. Read More


Indianapolis Business Journal: Startup Drug Firm Lands Veteran Help

A startup firm using Indiana University medical research to treat a fatal lung disease is raising money for clinical trials and has recruited a prominent life sciences veteran to lead the effort. Read More